Picture of Appili Therapeutics logo

APLI Appili Therapeutics Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-7.85%
3m-31.85%
6m-43.16%
1yr-90.71%
Volume Change (%)
10d/3m-67.92%
Price vs... (%)
52w High-94.3%
50d MA-6.07%
200d MA-60.9%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-1526.45%
Return on Equity-529.79%
Operating Margin-1770.48%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202331st Mar 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Appili Therapeutics EPS forecast chart

Profile Summary

Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is focused on the acquisition and development of medicines targeting infectious disease. The Company also focused on building and advancing a diverse portfolio of anti-infective programs. Its anti-infective portfolio includes ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir. The ATI-2307 is used for the treatment of invasive fungal infections with a near-term focus on those caused by Cryptococcus and Candida. The ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The ATI-1503 is a drug discovery program builds off the molecular structure of negamycin, a naturally occurring compound that can kill Gram-negative bacteria. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole. Metronidazole is a front-line antibiotic for the treatment of anaerobic bacterial and parasitic infections. The Favipiravir is an oral covid-19 antiviral candidate.

Directors

Last Annual
March 31st, 2022
Last Interim
March 31st, 2022
Incorporated
May 7th, 2015
Public Since
June 25th, 2019
No. of Employees
11
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconToronto Stock Exchange
Shares in Issue
71,266,120

APLI Share Price Performance

Upcoming Events for APLI

Appili Therapeutics Inc Annual Shareholders Meeting

Appili Therapeutics Inc Extraordinary Shareholders Meeting

Appili Therapeutics Inc Annual Shareholders Meeting

Q2 2023 Appili Therapeutics Inc Earnings Release

Q3 2023 Appili Therapeutics Inc Earnings Release

Similar to APLI

Picture of AEterna Zentaris logo

AEterna Zentaris

ca flag iconToronto Stock Exchange

Picture of Antibe Therapeutics logo

Antibe Therapeutics

ca flag iconToronto Stock Exchange

Picture of Aptose Biosciences logo

Aptose Biosciences

ca flag iconToronto Stock Exchange

Picture of Avicanna logo

Avicanna

ca flag iconToronto Stock Exchange

Picture of BELLUS Health logo

BELLUS Health

ca flag iconToronto Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email